MONTREAL, July 08, 2025 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the second quarter ended June 30, 2025 via news release on Monday, July 28, 2025 after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Monday, July 28, 2025 at 5:00 PM Easter ...

MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Sho ...

Shenzhen, China, July 08, 2025 (GLOBE NEWSWIRE) -- Baiya International Group Inc. (“BIYA” or the “Company”) (Nasdaq: BIYA), a human resource (“HR”) technology company utilizing its cloud-based internet platform to provide one-stop crowdsourcing recruitment and SaaS-enabled HR solutions, today announced that since its successful listing on the Nasdaq in March 2025, the Company has seen a steady rise in brand influence and significant acceleration in business growth. The Company’s core operating entity, Shenz ...

Core Insights - Upexi, Inc. reported a successful June 2025, with an 8% increase in its SOL balance and an 8% staking yield [2][7] - The company is focused on enhancing visibility and raising capital for shareholder benefits through various initiatives [2] Treasury Update - As of June 30, 2025, Upexi held 735,692 SOL, an increase of 8.2% from 679,677 SOL on May 28 [7] - The net asset value of the SOL holdings is approximately $113.8 million, based on a price of $154.74 per SOL [7] - Each common share represents approximately 0.0192 SOL or $2.97 [7] - Nearly all treasury SOL are staked, earning an ~8% yield [7] - About 58% of the portfolio consists of locked SOL purchased at a discount, providing built-in gains [7] Business Initiatives - Upexi's equity options are now listed on Nasdaq, enhancing visibility and liquidity [7] - The company is partnering with Superstate to tokenize its equity, allowing for 24/7 trading and broader investor access [7] - Upexi joined Webull's Corporate Connect Service Platform to increase market awareness among Webull's 24 million users [7] Solana Network Performance - Solana recorded significant growth in key metrics, including a 200% year-over-year increase in daily active addresses [9] - Daily transactions reached $3.0 billion, a 67% increase, while DEX volumes surged by 347% to $182 billion [9] - Application revenue grew by 33% to $147 million [9] Price Movement - SOL started June at $157 and ended nearly unchanged at $155, with a low of $132 on June 22 and a high of $165 on June 10 [8]

EINDHOVEN, The Netherlands, July 08, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) today announced it will release financial results for the second quarter 2025 after the close of normal trading on the NASDAQ Global Select Market on Monday, July 21, 2025. The company will host a conference call with the financial community on Tuesday, July 22, 2025, at 8:00 a.m. U.S. Eastern Daylight Time (EDT). Earnings Conference Call Details Interested parties may pre-register for the webcast or obtain ...

THORNTON, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today commented on its commercial progress and solar material development in the first half of 2025, as the Company looks ahead to continued growth and advancement in the second half of the year. “At the outset of the year, we sought to enter into a series of new pr ...

Core Viewpoint - ZyVersa Therapeutics, Inc. has received FDA authorization for Emergency Compassionate Use of its investigational drug Cholesterol Efflux Mediator™ VAR 200 for a patient with ApoCII amyloidosis, a condition with no effective treatment options available [1][4]. Group 1: Product Development and Clinical Trials - VAR 200 is currently in phase 2 development aimed at treating renal lipid accumulation, which is critical for protecting kidney function and preventing disease progression [5][8]. - The drug is being administered at the University of Miami under the supervision of Dr. Alessia Fornoni, who is also the inventor of VAR 200 [2]. - Preclinical studies have shown that VAR 200 can reduce cholesterol and lipid levels, protect against renal injury, and improve proteinuria in various kidney disease models [6][8]. Group 2: Company Overview and Future Directions - ZyVersa is focused on developing first-in-class drugs for renal and inflammatory diseases, leveraging proprietary technologies [9]. - The company is advancing a therapeutic pipeline that includes VAR 200 for kidney diseases and another product, Inflammasome ASC Inhibitor IC 100, targeting CNS and peripheral inflammatory diseases [9]. - The lead indication for VAR 200 is orphan kidney disease, specifically focal segmental glomerulosclerosis (FSGS), with ongoing trials expected to provide quicker proof-of-concept [7].

Core Viewpoint - POET Technologies Inc. has appointed Sohail Khan as a director and member of the Corporate Governance & Nominating Committee, effective July 7, 2025, to enhance its leadership and strategic initiatives in AI and other market segments [1][3]. Company Overview - POET Technologies specializes in designing and developing high-speed optical modules, optical engines, and light source products for the artificial intelligence systems market and hyperscale data centers [5]. - The company’s key innovation is the POET Optical Interposer™, which integrates electronic and photonic devices into a single chip, offering lower costs, reduced power consumption, and scalability for high production volumes [5]. - POET's products support high-speed optical communication (800G, 1.6T and above) and address bandwidth and latency challenges in AI systems, as well as integration issues in 5G networks and autonomous vehicle applications [5]. Leadership Changes - Sohail Khan brings extensive experience in high technology firms, including M&A expertise and leadership roles in various companies, enhancing POET's board with his strategic insights [2][3]. - The board size was reduced to five members following the retirement of Chris Tsiofas, with Mr. Khan's appointment increasing the board to six members [3]. Compensation Details - Mr. Khan was awarded 21,200 Restricted Stock Units (RSUs) that will vest on the first anniversary of the grant, based on a share price of CAD$7.70 [4].

Core Viewpoint - Jeffs' Brands Ltd has successfully completed the acquisition of Fort Products Limited, resulting in a significant equity stake in the newly merged entity, Fort Technology Inc, which is expected to enhance growth in the e-commerce sector [1][2][7]. Group 1: Acquisition Details - The acquisition transaction closed on July 7, 2025, with Jeffs' Brands selling all shares of Fort Products to Fort Technology for 100,000,000 common shares valued at approximately CAD 17.1 million (around $12.5 million) [2]. - Following the transaction, Jeffs' Brands holds a 75.02% equity stake in Fort Technology, which could increase to 83.29% upon meeting certain milestones [1][4]. - Fort Products is now a wholly-owned subsidiary of Fort Technology, which has changed its name from Impact Acquisitions Corp and is set to resume trading on the TSX Venture Exchange [3]. Group 2: Contingent Rights and Milestones - Jeffs' Brands is entitled to receive up to an additional 66,000,000 common shares contingent upon achieving specific milestones, including a successful listing on a U.S. Exchange and reaching annual revenues of at least USD 15 million by December 31, 2028 [4][5]. - The milestones include raising $8 million in equity or debt financing by July 7, 2029, and completing an uplisting transaction by July 7, 2027 [5]. Group 3: Strategic Implications - The transaction is expected to leverage Fort Products' innovative e-commerce platform, which specializes in high-margin products sold on the Amazon Marketplace, to drive significant growth in global online retail markets [7]. - Jeffs' Brands aims to transform the e-commerce landscape by creating and acquiring products to become market leaders, utilizing advanced technology and management insights [10].

Core Insights - BriaCell Therapeutics Corp. has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer, indicating a robust survival signal and well-tolerated profile for the treatment [1][4]. Patient Survival Data - The Phase 2 study included 54 heavily pre-treated metastatic breast cancer patients, with a median of 6 prior treatment lines [7]. - The most recent cohort of 25 patients achieved a one-year survival rate of 52%, with 11 patients remaining alive, including one at 38.3 months and another at 30.3 months [6][7]. - Survival rates in this cohort exceed current standard of care therapies for similar patient populations [6]. Expert Commentary - Experts have highlighted the potential of Bria-IMT to improve survival and tolerability for late-stage patients, especially those who have progressed despite treatment with checkpoint inhibitors and antibody-drug conjugates [4][6]. - The ongoing investigation in a Phase 3 randomized clinical trial aims to further assess the efficacy of Bria-IMT in combination with checkpoint inhibitors [4]. Comparative Analysis - Bria-IMT plus checkpoint inhibitors showed a 52% one-year survival rate compared to approximately 38-40% for other studies with fewer prior treatment lines [5][6]. - The study indicates that Bria-IMT may provide significant benefits for patients who have failed multiple lines of therapy, including those treated with ENHERTU and TRODELVY [6][7]. Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [8].